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Our previous study demonstrated that 29% of disabled and 13% of elderly Medicare beneficiaries reported CRN. 1 It is therefore not surprising that our study and other investigations have found that physicians often provide samples to patients burdened by prescription costs.
2,3 Important questions remain:
1) what is the effect of policies restricting free samples on patient's prescription drug utilization, expenditures, and health outcomes; and 2) are samples a cost-driver or safety net? We acknowledge our inability in this study to discern the mechanism explaining the strong association between CRN and free sample use because of the cross-sectional design of the study. Some argue that samples lead to overuse of expensive, brandname, medications in lieu of less expensive, evidence-based, treatments. 4 Despite these limitations, we found that 78% of elderly Medicare beneficiaries with CRN accessed free samples. We argue that the needs of these patients should be considered when adopting policies limiting free sample distribution. Physicians need to recognize that requests for free samples are a marker of possible CRN that requires further investigation. Indeed, Piette et al. found that most patients are reluctant to report CRN and most physicians do not ask about affordability. 5 Rather than offering free samples, physicians can switch patients to generic drugs, discontinue nonessential medicines, or refer patients to programs providing financial assistance.
For physicians who continue to distribute free samples, we recommend training on the influence of samples and other marketing devices. 6 Many physicians do not believe free samples influence prescribing. We recommend that medical licensing boards adopt policies requiring at least 1 hour of continuing medical education on the marketing of medications as a condition of license renewal for all prescribers. In this way, we might be able to effectively disseminate the message to all physicians that a "free sample" is not necessarily free.
